Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

American Tower

Alexandria Real Estate Equities

Broadcom

Carrier Global

Deere & Company

Ecolab

Edison

Southwest Airlines

Mastercard

PACCAR

Stryker

Southwest Airlines also said it will resume paying a dividend.

Paccar, Deere, and 10 More Companies That Raised Their Stock Dividends

Merck

Today's Research Daily features update on the Q4 earnings season and new research reports on Merck (MRK), Bristol-Myers (BMY) and Deere (DE).

Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers & Deere

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?

This top health stock stands out with its proven year-over-year earnings growth record, increased earnings estimates and hefty 2.7% dividend. The post Leading Health Stock With Rising Earnings Estimates Nears Buy Point appeared first on Investor's Business Daily.

Leading Health Stock With Rising Earnings Estimates Nears Buy Point

Amazon

Mergers and acquisitions have played a big part in the growth of these businesses.

2 Massive Companies That Have Doubled Their Sales in 5 Years

Collaboration will leverage Envisagenics' SpliceCore® AI platform for accelerated discovery and development of oncology therapeutic candidates NEW YORK , Nov. 29, 2022 /PRNewswire/ -- Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb  (NYSE: BMY). The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline.

Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Bristol Myers Squibb is a pharmaceutical powerhouse after its Celgene acquisition. The company's revenues in 2022 will be down slightly year-on-year as Revlimid sales fall from $12bn to ~$9bn after patent expiry.

Bristol Myers Squibb: Share Price Growth In 2022 Best For A Decade - But 2023 Could Better It

Amgen

Eli Lilly

Pfizer

Among the 19 companies that are expected to announce annual dividend increases in December are drugmakers Eli Lilly, Pfizer, Bristol Myers Squibb, and Amgen. Investors are also waiting for Merck's increase. We'll see several nice increases in December from other companies as well: Nucor, Mastercard, and Broadcom are all expected to announce 10%+ boosts.

4 Pharmaceutical Companies Among 19 To Announce Annual Dividend Increases In December

Shares of Bristol-Myers Squibb Company are up 28% year to date. Bristol-Myers Squibb is still attractively valued.

Bristol-Myers Squibb Is Still An Attractive Addition To Your Dividend Growth Portfolio

AbbVie

Johnson & Johnson

These businesses -- and dividends -- are built to last.

3 Dividend Stocks to Hold Forever

Bristol Myers (BMY) reported earnings 30 days ago. What's next for the stock?

Why Is Bristol Myers (BMY) Up 6.3% Since Last Earnings Report?

Biotech giant Bristol Myers (BMY) outperforms the industry and the S&P 500 Index as Eliquis and Opdivo maintain momentum despite generic competition for Revlimid.

Bristol Myers (BMY) Gains 24.2% YTD: What's in Store for 2023?

PRINCETON, N.J.--( BUSINESS WIRE )--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across its hematology portfolio at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in New Orleans, Louisiana, and virtually, from December 10 to 13, 2022. Data from more than 100 company-sponsored studies will be featured, including 34 oral presentations, highlighting the range of modalities, targets and research platforms the company is advancing and showcasing our commitment to scientific progress across hematologic diseases.

Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases

AstraZeneca

Both have outperformed the stock market this year.

2 Stocks to Buy Whether or Not a Recession Is Coming

Bristol-Myers Squibb Company (NYSE:BMY ) 4th Annual Wolfe Research Healthcare Conference November 16, 2022 3:20 PM ET Company Participants Chris Boerner - EVP and Chief Commercialization Officer Conference Call Participants Tim Anderson - Wolfe Research Tim Anderson Okay. Great. Well, thanks for joining us.

Bristol-Myers Squibb Company (BMY) Presents at 4th Annual Wolfe Research Healthcare Conference (Transcript)

3 pharmaceutical stocks to watch in the stock market right now.

3 Pharmaceutical Stocks For Your November 2022 Watchlist

Bristol Myers Squibb stock (NYSE: BMY) is up 15% in a month, slightly outperforming the broader S&P500 index, up 11%.

Up 15% In A Month Will Bristol Myers Squibb Stock Continue To See Higher Levels?

Shares of this pharmaceutical stock have surged higher in 2022.

Is This Blue-Chip Dividend Stock a Buy?

These two top biopharma stocks are crushing the 2022 bear market.

2 Ultra-Safe Passive Income Stocks to Buy Right Now

Biopharma leader Bristol-Myers Squibb posted solid Q3 results, despite competition from generic-drug makers for its popular cancer pill. The post Biopharma Bristol-Myers Unfazed By Generic Competition For Cancer Cash Cow appeared first on Investor's Business Daily.

Biopharma Bristol-Myers Unfazed By Generic Competition For Cancer Cash Cow

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference

Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference

BioNTech SE

Moderna

With the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according to Acumen Research and Consulting.

The 7 Best Pharma Stocks to Buy Now

Just because the stock market is going haywire doesn't mean you have to sit on the sidelines.

News for Bristol-Myers Stock (BMY)